Butalbital Compound Alternatives Compared
| Butalbital Compound | Ubrelvy | Erenumab |
|
|---|
| Butalbital Compound (aspirin / butalbital / caffeine) | Ubrelvy (ubrogepant) | Erenumab |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Migraine, Pain, Headache. Butalbital Compound may also be used for purposes not listed in this medication guide. |
Prescription only
Ubrelvy is a prescription medicine that may be used to treat acute migraine attacks in adults and works by blocking the effects of a protein, called CGRP that is thought to play a role in migraine... View more |
Prescription only
Prescribed for Migraine Prevention, Headache, Migraine. Erenumab may also be used for purposes not listed in this medication guide. |
Related suggestions Migraine
|
|||||||
| More about (aspirin / butalbital / caffeine) | More about Ubrelvy (ubrogepant) | More about Erenumab | ||||||||
| Ratings & Reviews | ||||||||||
|
Butalbital Compound has an average rating of 9.1 out of 10 from a total of 27 ratings on Drugs.com. 88% of reviewers reported a positive effect, while 0% reported a negative effect. |
Ubrelvy has an average rating of 6.2 out of 10 from a total of 249 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 38% reported a negative effect. |
Erenumab has an average rating of 5.2 out of 10 from a total of 639 ratings on Drugs.com. 38% of reviewers reported a positive effect, while 43% reported a negative effect. |
||||||||
| Drug Class | ||||||||||
| Side Effects | ||||||||||
| Generic Availability | ||||||||||
| Lower cost generic approved |
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Ubrelvy prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms Available | ||||||||||
|
N/A |
|
N/A |
||||||||
| Brand Names | ||||||||||
| Other aspirin / butalbital / caffeine brands include: Farbital, Fiorinal, Fiormor, Fiortal, Fortabs |
N/A |
Aimovig | ||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
|
35 hours |
7 hours |
672 hours |
||||||||
| CSA Schedule ** View glossary of terms | ||||||||||
|
Moderate abuse potential
Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 859 drugs are known to interact with Butalbital Compound:
|
A total of 224 drugs are known to interact with Ubrelvy:
|
A total of 2 drugs are known to interact with Erenumab:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
|
||||||||||
| First Approval Date | ||||||||||
|
N/A |
December 23, 2019 |
N/A |
||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient resources | ||||||||||
|
N/A |
||||||||||
| Professional Resources | ||||||||||
|
N/A |
||||||||||
| Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.